1332329-48-2

Upstream product

• 1254059-33-0 1-(2-methyl-5-nitro-phenyl)-piperidin-4-one 
• 1254059-22-7 8-(2-methyl-5-nitro-phenyl)-1,4-dioxa-8-aza-spiro[4.5]decane 
• 593-85-1 guanidine carbonate 
• 1332329-35-7 3-dimethylaminomethylene-1-(2-methyl-5-nitro-phenyl)-piperidin-4-one 
• 7745-93-9 2-bromo-4-nitrotoluene 

Downstream Products

• 1332329-49-3 6-(2-methyl-5-nitro-phenyl)-2-[4-(4-methyl-piperazine-1-carbonyl)phenylamino]-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one 
• 1332329-50-6 6-(5-amino-2-methyl-phenyl)-2-[4-(4-methyl-piperazine-1-carbonyl)-phenylamino]-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one 
• 1332328-30-9 N-(4-methyl-3-{2-[4-(4-methyl-piperazine-1-carbonyl)phenylamino]-5-oxo-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl}-phenyl)-3-trifluoromethyl-benzamide 

Relevant academic research and scientific papers

BICYCLIC COMPOUNDS AND THEIR USES AS DUAL C-SRC / JAK INHIBITORS

The present invention relates to substituted aromatic bicyclic compounds containing pyrimidine and pyridine rings of formula (I) having the structure as well as pharmaceutically acceptable salts thereof. The compounds of the present invention are useful as tyrosine kinase inhibitors, preferably SRC family kinases (SFKs) inhibitors, in particular as multi SFK/JAK. kinases inhibitors and even preferably as dual c-SRC/JAK kinases inhibitors, thereby inhibiting the STAT3 activation and therefore abnormal growth of particular cell types. Notably, the compounds of the present invention are useful for the treatment or inhibition of certain diseases that are the result of deregulation of STAT3.